Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation.

Hepatocellular adenomas (HCA) are benign liver tumors predominantly developed in women using oral contraceptives. Here, exome sequencing identified recurrent somatic FRK mutations that induce constitutive kinase activity, STAT3 activation, and cell proliferation sensitive to Src inhibitors. We also found uncommon recurrent mutations activating JAK1, gp130, or β-catenin. Chromosome copy number and methylation profiling revealed patterns that correlated with specific gene mutations and tumor phenotypes. Finally, integrative analysis of HCAs transformed to hepatocellular carcinoma revealed β-catenin mutation as an early alteration and TERT promoter mutations as associated with the last step of the adenoma-carcinoma transition. In conclusion, we identified the genomic diversity in benign hepatocyte proliferation, several therapeutic targets, and the key genomic determinants of the adenoma-carcinoma transformation sequence.

[1]  S. Mustjoki,et al.  Somatic STAT3 mutations in large granular lymphocytic leukemia. , 2012, The New England journal of medicine.

[2]  E. Clappier,et al.  Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia , 2008, The Journal of experimental medicine.

[3]  J. Zucman‐Rossi,et al.  Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas , 2011, The Journal of experimental medicine.

[4]  J. Tran van Nhieu,et al.  GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. , 2012, Journal of hepatology.

[5]  M. Taketo,et al.  Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. , 2002, Cancer research.

[6]  Chi-Hung Lin,et al.  Chromosomal analysis of hepatic adenoma and focal nodular hyperplasia by comparative genomic hybridization , 2002, Genes, chromosomes & cancer.

[7]  Yiling Lu,et al.  Rak functions as a tumor suppressor by regulating PTEN protein stability and function. , 2009, Cancer cell.

[8]  Thomas D. Wu,et al.  Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events , 2012, Genome research.

[9]  Gary L. Gallia,et al.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.

[10]  S. Imbeaud,et al.  Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma , 2012, Nature Genetics.

[11]  J. Zucman‐Rossi,et al.  Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. , 2013, Journal of hepatology.

[12]  Lynda Chin,et al.  Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2013, Science.

[13]  Cristel G. Thomas,et al.  Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry , 2007, Hepatology.

[14]  J. Zucman‐Rossi,et al.  Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma , 2013, Oncoimmunology.

[15]  K. Ishak,et al.  Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. , 1979, Journal of the American Medical Association (JAMA).

[16]  Jongdae Lee,et al.  Signal Transducer and Activator of Transcription 3 (STAT3) Protein Suppresses Adenoma-to-carcinoma Transition in Apcmin/+ Mice via Regulation of Snail-1 (SNAI) Protein Stability* , 2012, The Journal of Biological Chemistry.

[17]  J. Zucman‐Rossi,et al.  Genotype–phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC , 2006, Hepatology.

[18]  J. Zucman‐Rossi,et al.  Bi-allelic inactivation of TCF1 in hepatic adenomas , 2002, Nature Genetics.

[19]  M. Yaniv,et al.  Hepatocyte nuclear factor 1alpha gene inactivation impairs chromatin remodeling and demethylation of the phenylalanine hydroxylase gene , 1997, Molecular and cellular biology.

[20]  E. Casanova,et al.  Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. , 2010, Gastroenterology.

[21]  A. Cadoret,et al.  Hepatomegaly in Transgenic Mice Expressing an Oncogenic Form of β-Catenin , 2001 .

[22]  Susan J Clark,et al.  DNA methylation and gene silencing in cancer: which is the guilty party? , 2002, Oncogene.

[23]  D. Schadendorf,et al.  TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.

[24]  Jessica Zucman-Rossi,et al.  Hepatocellular benign tumors-from molecular classification to personalized clinical care. , 2013, Gastroenterology.

[25]  J. Zucman‐Rossi,et al.  Hepatocellular adenoma management and phenotypic classification: The Bordeaux experience , 2009, Hepatology.

[26]  M. Szyf,et al.  Definition of the landscape of promoter DNA hypomethylation in liver cancer. , 2011, Cancer research.

[27]  Bin Tean Teh,et al.  Exome sequencing of liver fluke–associated cholangiocarcinoma , 2012, Nature Genetics.

[28]  A. Cadoret,et al.  Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin. , 2001, Cancer research.

[29]  J. Tran van Nhieu,et al.  Spectrum of HNF1A Somatic Mutations in Hepatocellular Adenoma Differs From That in Patients With MODY3 and Suggests Genotoxic Damage , 2010, Diabetes.

[30]  J. Darnell,et al.  Stat3 Activation Is Required for Cellular Transformation by v-src , 1998, Molecular and Cellular Biology.

[31]  J. Turkson,et al.  Stat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation , 1998, Molecular and Cellular Biology.

[32]  J. Zucman‐Rossi,et al.  Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation. , 2003, Gastroenterology.

[33]  Niruthika Sritharan,et al.  Genomic landscape of non-small-cell lung cancer in smokers and never-smokers , 2013, Thorax.

[34]  E. E. Gresch.  Genetic Alterations During Colorectal-Tumor Development , 1989 .

[35]  Shigeru Chiba,et al.  Identification of a SRC‐like tyrosine kinase gene, FRK, fused with ETV6 in a patient with acute myelogenous leukemia carrying a t(6;12)(q21;p13) translocation , 2005, Genes, chromosomes & cancer.

[36]  S. Constantinescu,et al.  JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation , 2005, Journal of Biological Chemistry.

[37]  Kiran C. Bobba,et al.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.

[38]  M. Karin,et al.  Inflammation and oncogenesis: a vicious connection. , 2010, Current opinion in genetics & development.

[39]  J. Zucman‐Rossi,et al.  Hepatocellular adenomas: Magnetic resonance imaging features as a function of molecular pathological classification , 2008, Hepatology.

[40]  Mark Bieda,et al.  Analysis of the mechanisms mediating tumor-specific changes in gene expression in human liver tumors. , 2008, Cancer research.

[41]  Susan O'Brien,et al.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.

[42]  E. Letouzé,et al.  Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis , 2010, Genome Biology.

[43]  S. Imbeaud,et al.  Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours , 2009, Nature.